XTAP vs. LABD
Compare and contrast key facts about Innovator U.S. Equity Accelerated Plus ETF (XTAP) and Direxion Daily S&P Biotech Bear 3x Shares (LABD).
XTAP and LABD are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. XTAP is an actively managed fund by Innovator. It was launched on Apr 1, 2021. LABD is a passively managed fund by Direxion that tracks the performance of the S&P Biotechnology Select Industry Index (-300%). It was launched on May 28, 2015.
Performance
XTAP vs. LABD - Performance Comparison
Loading graphics...
XTAP vs. LABD - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
XTAP Innovator U.S. Equity Accelerated Plus ETF | 1.66% | 17.58% | 14.26% | 23.46% | -14.68% | 11.87% |
LABD Direxion Daily S&P Biotech Bear 3x Shares | -22.25% | -70.07% | -21.43% | -41.77% | -32.68% | 21.59% |
Returns By Period
In the year-to-date period, XTAP achieves a 1.66% return, which is significantly higher than LABD's -22.25% return.
XTAP
- 1D
- 0.08%
- 1M
- 0.65%
- YTD
- 1.66%
- 6M
- 4.34%
- 1Y
- 16.29%
- 3Y*
- 16.22%
- 5Y*
- —
- 10Y*
- —
LABD
- 1D
- -22.42%
- 1M
- -7.39%
- YTD
- -22.25%
- 6M
- -59.03%
- 1Y
- -82.24%
- 3Y*
- -55.49%
- 5Y*
- -38.61%
- 10Y*
- -57.45%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
XTAP vs. LABD - Expense Ratio Comparison
XTAP has a 0.79% expense ratio, which is lower than LABD's 1.06% expense ratio.
Return for Risk
XTAP vs. LABD — Risk / Return Rank
XTAP
LABD
XTAP vs. LABD - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Innovator U.S. Equity Accelerated Plus ETF (XTAP) and Direxion Daily S&P Biotech Bear 3x Shares (LABD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| XTAP | LABD | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.14 | -0.96 | +2.10 |
Sortino ratioReturn per unit of downside risk | 1.76 | -2.04 | +3.81 |
Omega ratioGain probability vs. loss probability | 1.44 | 0.77 | +0.68 |
Calmar ratioReturn relative to maximum drawdown | 1.43 | -0.91 | +2.34 |
Martin ratioReturn relative to average drawdown | 9.78 | -1.17 | +10.95 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| XTAP | LABD | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.14 | -0.96 | +2.10 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | -0.40 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | -0.60 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.69 | -0.54 | +1.23 |
Correlation
The correlation between XTAP and LABD is -0.52. This indicates that the assets' prices tend to move in opposite directions. Negative correlation can be particularly beneficial for diversification and risk management, as one asset may offset the losses of the other during market fluctuations.
Dividends
XTAP vs. LABD - Dividend Comparison
XTAP has not paid dividends to shareholders, while LABD's dividend yield for the trailing twelve months is around 5.82%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
XTAP Innovator U.S. Equity Accelerated Plus ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LABD Direxion Daily S&P Biotech Bear 3x Shares | 5.82% | 6.67% | 4.68% | 6.13% | 0.53% | 0.00% | 3.94% | 1.75% | 0.81% |
Drawdowns
XTAP vs. LABD - Drawdown Comparison
The maximum XTAP drawdown since its inception was -22.13%, smaller than the maximum LABD drawdown of -99.99%. Use the drawdown chart below to compare losses from any high point for XTAP and LABD.
Loading graphics...
Drawdown Indicators
| XTAP | LABD | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -22.13% | -99.99% | +77.86% |
Max Drawdown (1Y)Largest decline over 1 year | -11.83% | -88.09% | +76.26% |
Max Drawdown (5Y)Largest decline over 5 years | — | -97.73% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -99.98% | — |
Current DrawdownCurrent decline from peak | 0.00% | -99.99% | +99.99% |
Average DrawdownAverage peak-to-trough decline | -3.57% | -90.78% | +87.21% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 1.73% | 68.46% | -66.73% |
Volatility
XTAP vs. LABD - Volatility Comparison
The current volatility for Innovator U.S. Equity Accelerated Plus ETF (XTAP) is 0.77%, while Direxion Daily S&P Biotech Bear 3x Shares (LABD) has a volatility of 36.88%. This indicates that XTAP experiences smaller price fluctuations and is considered to be less risky than LABD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| XTAP | LABD | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 0.77% | 36.88% | -36.11% |
Volatility (6M)Calculated over the trailing 6-month period | 2.52% | 59.06% | -56.54% |
Volatility (1Y)Calculated over the trailing 1-year period | 14.33% | 87.11% | -72.78% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 14.60% | 96.40% | -81.80% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 14.60% | 96.40% | -81.80% |